The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ABBVIE INC. | COM | 00287Y109 | 92 | 1,000 | SH | SOLE | 1,000 | 0 | 0 | ||
| ALLERGAN PLC | SHS | G0177J108 | 57,351 | 344,000 | SH | SOLE | 344,000 | 0 | 0 | ||
| APRICUS BIOSCIENCES INC. | COM NEW | 03832V307 | 564 | 1,447,906 | SH | SOLE | 1,447,906 | 0 | 0 | ||
| BIOGEN INC. | COM | 09062X103 | 134,049 | 461,858 | SH | SOLE | 461,858 | 0 | 0 | ||
| INNOVIVA INC. | COM | 45781M101 | 62,583 | 4,535,000 | SH | SOLE | 4,535,000 | 0 | 0 | ||
| INTERCEPT PHARMACEUTICALS INC. | COM | 45845P108 | 53,308 | 635,300 | SH | SOLE | 635,300 | 0 | 0 | ||
| IRONWOOD PHARMACEUTICALS INC. | COM CL A | 46333X108 | 64,378 | 3,367,100 | SH | SOLE | 3,367,100 | 0 | 0 | ||
| MEDICINES CO. | COM | 584688105 | 70,537 | 1,922,000 | SH | SOLE | 1,922,000 | 0 | 0 | ||
| NOVELION THERAPEUTICS INC. | COM NEW | 67001K202 | 3,772 | 1,025,000 | SH | SOLE | 1,025,000 | 0 | 0 | ||
| SHIRE PLC | SPONSORED ADR | 82481R106 | 52,159 | 309,000 | SH | SOLE | 309,000 | 0 | 0 | ||